Kathrin Brockmann

Hoppe Seyler Str. 3
Tuebingen, BW 72076, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 183 publications

Regulatory endorsement for the application of α-synuclein seed amplification assay as a susceptibility and risk biomarker for clinical trials targeting synucleinopathies.

Regulatory endorsement for the application of α-synuclein seed amplification assay as a susceptibility and risk biomarker for clinical trials targeting synucleinopathies.

Journal: Journal of Parkinson's disease
Published: July 24, 2026

The PET tracer [11C]MODAG-005 targets alpha-synuclein aggregates in the brain.

The PET tracer [11C]MODAG-005 targets alpha-synuclein aggregates in the brain.

Journal: Science translational medicine
Published: May 27, 2026

Identification and phenotypic profiling of subgroups with distinct cognitive aging trajectories.

Identification and phenotypic profiling of subgroups with distinct cognitive aging trajectories.

Journal: GeroScience
Published: April 20, 2026

Inter-assay and Inter-site Performance of Alpha-Synuclein Seed Amplification Assays in Synucleinopathies: A Multicenter 2 × 2 Protocol Comparison.

Inter-assay and Inter-site Performance of Alpha-Synuclein Seed Amplification Assays in Synucleinopathies: A Multicenter 2 × 2 Protocol Comparison.

Journal: Neurology and therapy
Published: March 04, 2026

Genetic variation in antidiabetic drug targets: associations with Parkinson's disease risk and age at onset.

Genetic variation in antidiabetic drug targets: associations with Parkinson's disease risk and age at onset.

Journal: NPJ Parkinson's disease
Published: January 20, 2026

Preventing Parkinson's disease in the context of movement disorders: a narrative review of current evidence and future directions.

Preventing Parkinson's disease in the context of movement disorders: a narrative review of current evidence and future directions.

Journal: Neurological research and practice
Published: January 10, 2026

Clinical correlates of a negative cerebrospinal fluid α-synuclein seed amplification assay result in Parkinson's disease.

Clinical correlates of a negative cerebrospinal fluid α-synuclein seed amplification assay result in Parkinson's disease.

Journal: NPJ Parkinson's disease
Published: December 15, 2025

Impact of genetic variants in the longevity gene PPARGC1A and cerebrospinal fluid PPARγ levels on clinical trajectories in Parkinson's disease: Potential biomarkers for neurodegeneration and ageing.

Impact of genetic variants in the longevity gene PPARGC1A and cerebrospinal fluid PPARγ levels on clinical trajectories in Parkinson's disease: Potential biomarkers for neurodegeneration and ageing.

Journal: Parkinsonism & related disorders
Published: October 31, 2025

Quantification of cerebrospinal fluid α-synuclein seeds by endpoint dilution seed amplification assay in Parkinson's disease.

Quantification of cerebrospinal fluid α-synuclein seeds by endpoint dilution seed amplification assay in Parkinson's disease.

Journal: NPJ Parkinson's disease
Published: August 28, 2025

Genome-wide association study of copy number variations in Parkinson's disease.

Genome-wide association study of copy number variations in Parkinson's disease.

Journal: NPJ Parkinson's disease
Published: August 24, 2025

Genome-wide association study of REM sleep behavior disorder in Parkinson's disease.

Genome-wide association study of REM sleep behavior disorder in Parkinson's disease.

Journal: NPJ Parkinson's disease
Published: June 30, 2025

Blood phosphorylated tau elevation as a biomarker in immunoglobulin light chain and transthyretin amyloidosis.

Blood phosphorylated tau elevation as a biomarker in immunoglobulin light chain and transthyretin amyloidosis.

Journal: Nature medicine
Published: June 25, 2025
Showing 1-12 of 183

Last Updated: 09/26/2026